Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04625907 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Study acronym: FaR-RMS
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 90 to 128v5
  2. Site details revised at 1 of 90 sitesv4
  3. Secondary endpoints: 26 to 28v3
  4. Study sites: 2 to 90
    • Interventions: Actinomycin D (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Ifosfamide (Drug), Irinotecan (Drug), Temozolomide (Drug), Vincristine… to Actinomycin D (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Ifosfamide (Drug), Irinotecan (Drug), Regorafenib (Drug), Temozolomide…
    • Eligibility criteria expanded, about 137 words
    • Secondary endpoints revised (26)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Birmingham
44 trials monitored
See 3 trials at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Trial Details
NCT Number NCT04625907
Lead Sponsor University of Birmingham
Conditions
(from sponsor)		 Rhabdomyosarcoma
Related terms Rhabdomyosarcoma
Enrollment 1,672 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov